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http://www.biomedcentral.com/1471-2415/15/12RESEARCH ARTICLE Open AccessTransglutaminase binding fusion protein linked to
SLPI reduced corneal inflammation and
neovascularization
Juan P Salica1,2, Diego Guerrieri3, Paulo Maffia3, Juan O Croxatto4, H Eduardo Chuluyan3 and Juan E Gallo1,2*Abstract
Background: To study the effect of topical administration of a fusion protein (PF-MC) made up of N-terminal
portion of the protease inhibitor Trappin-2 (which is a substrate of transglutaminasa-2) and SLPI (protein with anti-
inflammatory, anti-bacterial and anti-viral ability), in an animal model of corneal inflammation and angiogenesis.
Methods: An alkali injury was produced with a filter paper of 3 mm with 1 N NaOH during 40 seconds on the
right cornea of 36 male Sprague Dawley rats, under general anesthesia. Animals were divided into three groups
according to treatment. Group 1 was treated with 10 ul of PF-MC (200 ug/ml; n = 12), Group 2, with 10 ul of SLPI
(200 ug/ml; n = 12) and Group 3 was treated with buffer (10 ul; n = 12) topically administered four times a day for
up to 7 days. Half of the animals were sacrificed at day 3 before making a re-epithelialization time analysis with
fluorescein staining at 18 and 24 hours. In the remaining animals corneal opacity was studied and digital photographs
were taken at day 7 before doing euthanasia. Eyes were processed for histology and immunofluorescence.
Results: Corneal ulcerated area was significantly lower in PF-MC treated animals compared to SLPI and buffer-treated
animals at 18 hours and 24 hours postinjury. A clear cornea and fundus red reflex was only found among PF-MC
treated animals. Histological analysis revealed a stratified corneal epithelium with at least three layers in all PF-MC
animals at day 7. In this group there was a reduced number of PMNs in the corneal stroma at 3 and 7 days of
follow-up. Besides, corneal neovascularization was much more extended in SLPI and Buffer animals than in animals
treated with PF-MC.
Conclusions: The binding of SLPI with Cementoin to transglutaminase seems to be an effective strategy to treat
corneal inflammation and angiogenesis.
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Alkali injuryBackground
The use of steroids in corneal inflammatory diseases is
quite common [1-3]. Corticoids chronic use can cause
ocular side effects as glaucoma and cataracts and affect
corneal epithelialization [4-6]. Because of these prob-
lems other anti-inflammatory drugs are being tested,
such as the physiological serine protease inhibitors SLPI
(secretory leucocyte protease inhibitor) and Elafin. These* Correspondence: jgallo06@gmail.com
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(PMNs) elastase but also inhibit the translocation of
the transcription factor NFkB (nuclear factor kappa-light-
chain-enhancer of activated B cells) to the core hindering
the activation of pro-inflammatory genes [7].
The proteolysis inhibitory action plays an important
role in the control of tissue damage produced by prote-
ases in the inflammatory sites. A strict balance between
proteases and the inhibitory effect is indispensable in
wound healing and in inflammatory disorders [8]. Unbal-
ance occurs in various inflammatory diseases as fibrocystic
disease, chronic bronchitis, emphysema associated to smo-
king and ulcers in inflammatory bowel disease [9-12].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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fied as protease inhibitors in mucosal secretions. In recent
years, our laboratory investigated the role of SLPI in sev-
eral inflammatory processes, such as orchitis autoinm-
mune and tuberculosi [13]. Therapies with SLPI are not
easy to maintain because of SLPI short half-life in serum
[7]. In order to improve the bioactive capabilities of SLPI
some modifications at the molecular level were performed
recently in our laboratory (unpublished results).
Transglutaminase (TG) is a group of 9 enzymes that
catalyze the formation of an isopeptide bond between a
free amine group and the acyl group at the end of the
side chain of protein- or peptide-bound glutamine. These
enzymes are involved in processes such as inflammation,
re-epithelialization, neovascularization and synthesis of
fibrous extracellular matrix. TG2 is located in the cell
nucleus, the cytoplasmic matrix and membrane com-
partments [14]. TG2 overexpresses at the inflammatory
site and activates PLA2, NFkB and MAPK stimulating
the inflammatory response. TG2 has been studied on
the eye and its relations with different pathologies. It is
involved in the pathophysiology of wound healing, pte-
rygium, dry eye and allergic conjunctivitis, among others
[15,16]. Therefore, there is a strong hypothesis that inhi-
biting TG2 could be beneficial for the cornea at least at
some point of the inflammatory process.Figure 1 Method used to evaluate the corneal neovascularization (CN
to endothelium. B: Sample of a cornea coloured with hematoxylin and eos
The vessels identified in each field (black arrows) counted as positive. C: Sc
D: Sample of a cornea stained with h&e, black circles marked the 40X fieldCombining the concepts previously exposed, the SLPI
gene was fused to the N-terminal portion of the protease
inhibitor Trappin-2 (cementoin), and expressed in a re-
combinant form as a fusion protein, designated PF-MC.
This fusion protein was able to anchor at the different
sites where the TG2 is expressed. Immobilized in this
way, it allows the SLPI molecule to act in a localized
fashion, and probably to increase the half-life of the pro-
tein. Therefore, the molecule is retained in the site
where the transglutaminase enzyme is present, particu-
larly through TG2 [17]. In this way, the biological active
agent has a longer half-life in the specific site of therapy
and a lower plasmatic degradation and would silence the
TG2 pro-inflammatory activity [18]. This mechanism is
especially useful for topical eye treatments because blin-
king accelerates drugs washed-up.
Corneal alkali injury cause very important damage to
the eye. There is a great inflammation and release of col-
lagenases as well as proteases that severely damage the
corneal tissue [19]. The inhibition of the NFkB pathway,
which is activated by most inflammatory cytokines, will
probably reduce the magnitude of the inflammatory
process, improving wound healing. For this purpose, we
aimed at evaluating the topical effect of the above men-
tioned fusion protein in a rat model of corneal alkali in-
jury. Results shown herein are promising.V). A: The Corneas were divided into thirds from epithelial surface
in (h&e). Blue lines show the virtual division in thirds of the corneas.
hematic cornea showing 40X fields from the periphery to the center.
s used to measure CNV extension.
Figure 2 Corneal re-epithelialization time. A: Digital pictures of alkali-injured rat corneas treated with PF-MC, SLPI and Buffer, stained with
fluorescein under cobalt blue light at 18 and 24 hs. B-C: Percentage of cornea with epithelial defect (including ulceration) at each healing interval.
The results are expressed with M ± SEM.
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Experimental design
Thirty-six male Sprague–Dawley rats (12 weeks old)
were provided by CNEA (Comisión Nacional de Energía
Atómica, Buenos Aires, Argentina). The animals were ini-
tially examined and screened for any preexisting ophthalmicFigure 3 Clinical digital photographs of rat corneas at day 7 after alk
observation shows presence of corneal stromal abscesses marked with blac
opacity grade of each treated group, classified according to Fantes et al.lesion. General anesthesia was induced using isoflurane and
then an alkali injury was produced with a filter paper of
3 mm with 1 N NaOH during 40 seconds on the central
part of the right cornea [20]. Then, the ocular surface was
gently washed with 5 ml of saline solution with 35G can-
nula. Animals were divided into three groups according toali-injury treated with PF-MC, SLPI or Buffer. A: Macroscopic
k circle in SLPI and Buffer groups. B: Scatter dot plot showing corneal
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3) Elution Buffer. Therapy was applied topically 10 ul four
times daily. The first dose was administered 30 minutes
after the lesion was caused. Six animals of each group were
euthanized at 3 and 7 days post lesion, respectively. All ex-
perimental procedures were done under the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision
Research and approved by the Austral University’s Animal
Care and Use Committee.
Preparation of PF-MC
The expression and purification of recombinant protein
PF-MC protein was performed from E. coli BL21-Codon
Plus-RIL (Stratagene, Darmstadt, Hessen, Germany). The
bacterial pellets were lysed by ultrasound and centrifuged.
The soluble fraction was recovered and added to a column
of Nickel-nitrilotriacetic acid (Ni-NTA) (Qiagen GmbH,
Hilden, Westphalia, Germany), allowing the binding of
the tail of histidines present in the protein. The PF-MCFigure 4 Corneal epithelialization at day 7 after alkali-injury treated w
A: Buffer. B: SLPI. C: PF-MC. D: Healthy control.protein retained in the column was eluted by adding 2 ml
of 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole;
pH = 8 (elution buffer 250). To reduce the concentration
of imidazole in the samples of proteins, the eluates were
subjected to a dialysis in phosphate buffer having a final
concentration of 2.5 mM. The dialysis was performed
overnight at 4°C, and subsequently the protein was recov-
ered and aliquoted as well as the dialysis buffer (to be used
as controls in the assays). After the purification and in
order to remove the residual bacterial LPS polymyxin B-
agarose agar was washed with dialysis buffer. The protein
PF-MC was recovered by centrifugation of the agar. The
quantification of protein concentration was performed
with a MicroBCA (Pierce, USA) kit according to the man-
ufacturer’s instructions.
Evaluation of corneal re-epithelialization time
Corneal re-epithelialization following alkali burn was
studied by fluorescent dye staining of the cornea. Areasith PF-MC, SLPI and Buffer. Histology of corneas stained with h&e.
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stained area indicates complete re-epithelialization. Six
eyes of each group were stained with fluorescein dye and
examined every 6 hours under an operating microscope
(Zeiss S4, Germany) adding cobalt blue light. Digital pic-
tures were taken at 18 and 24 hours of the injury using
a Digital Camera (20.1 megapixel; Nikon, Coolpix S3500,
Japan) with a Microscope Ocular Adaptor. Pixels of the
stained area were measured with Adobe Photoshop after
standardizing the size of the corneas. Percentage of ulcer-
ated cornea was calculated. The results were presented
as mean ± standard error of the mean. To study the
statistical difference between groups, we applied Kruskal-
Wallis test.
Evaluation of corneal opacity
The corneal opacity was evaluated using a slit-lamp bio-
microscope (Haag-Streit, Germany) at day 7. Findings
were classified according to Fantes et al. [21]. Briefly,
Grade 0: complete clear cornea without any trace of
haze. Grade 0.5: a faint haze detectable only by oblique
illumination. Grade1: mild haze but not interfering with
visibility of iris details. Grade 2: more prominent haze
with mild obscuration of iris details. Grade 3: opacity of
moderate density easily detectable under direct illumin-
ation with partial obscuration of iris details. Grade 4:
complete opacity with no visibility of structures in the
anterior chamber. The results are presented as mean ±
standard error of the mean. To study the statistical dif-
ference between groups, we applied Kruskal-Wallis test.
We studied and analyzed corneas with the presence of
abscess.Figure 5 Total cells count of corneas at day 7 post-injury, treated wit
of the cornea plus the PMN in one 40X field al the periphery of the corneaHistological examination
Animals were euthanized at day 3 and 7. The eyeballs
were extracted and the cornea dissected. Then, the cor-
nea was processed for cryosections of 15 microns thick-
ness and stained with hematoxyline and eosine. Four
sections of each cornea were examined under an Eclipse
Microscope (Nikon, Tokyo, Japan). The evaluation of the
cornea included the morphology of cells and number of
layers of the corneal epithelium; the count of cells in the
stroma; the identification and topographical localization
of neovessels. The analysis was carried out masked by
two examiners. The difference between the two examiners
was tested.
Neovascularization analysis. The cornea was schematic-
ally divided into thirds from epithelial surface to endothe-
lium in order to classify neovessels as superficial, medial
and deep (Figure 1A-B). The extension of neovasculariza-
tion was recorded according to the number of micro-
scopic fields of X40 magnification containing vessels from
the periphery to the center of the cornea (Figure 1C-D).
Immunofluorescense analysis
Rats were euthanized 7 days postinjury and the corneas
were excised, fixed in 4% paraformaldehyde for 6 hours
(Sigma-Aldrich, St Louis, MO). They were then immersed
for cryoprotection in 4 concentrations of glucose (5%,
7.5%, 10% and 20% overnight). The eyes were embedded
in Cryoplast (Biopack, Argentina) and frozen with liquid
nitrogen. The 15-micron thick cryosections were first in-
cubated overnight at 4°C with anti-mouse polyclonal anti-
body against vascular endothelial growth factor (VEGF)
(1:500) (Santa Cruz Biotechnology Inc., 2145 Delawareh PF-MC, SLPI or Buffer. Count of PMN in one 40X field at the center
.
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incubated for 30 minutes with donkey anti-mouse IgG-R
(SC-2300 Santa Cruz Biotechnology Inc., 2145 Delaware
Avenue Santa Cruz, CA, USA) and mounted with gly-
cerin. The evaluation was performed using immunofluor-
escence microscope (Nikon Eclipse, Tokyo, Japan).
Statistical analysis
The statistical analysis was performed with Prism 6.0 soft-
ware. To study the statistical difference between groups,Figure 6 Polimorphonuclear count at the center and periphery of cor
Buffer. A: Microscopic picture (40X). Black arrow indicates a PMN cell. B: Co
a field at the periphery. C: Statistic table of the PMN count at the center an
periphery excluding the cases with stromal abscess.we applied Kruskal-Wallis test. The significance level was
set at p < 0.05.
Results
Evaluation of corneal re-epithelialization time
At 18 hours after lesion, in the group of PF-MC trea-
ted animals there was the first cornea with complete
re-epithelialization following alkali burn. At 24 hours
postinjury this group and the SLPI group had 4 and 3
complete re-epithelialized corneas respectively. At thisneas at day 7 after alkali-injury treated with PF-MC, SLPI or
lumn chart of number of PMN in a 40X visual field at the center plus
d periphery. D: Statistic table of PMN count at the center and
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neas of buffer treated animals (Figure 2). The rate of
corneal ulcerated area was significantly lower in PF-
MCP treated animals compared to that seen in SLPI and
buffer treated animals 18 hours postinjury (Figure 2B).
The difference between PF-MC and Buffer groups re-
mained similar 24 hours after injury. At this time inter-
val the comparison between SLPI and PF-MC treated
animals did not show a statistically significant difference
(Figure 2C).
Macroscopic analysis
Corneal clarity was only seen in animals treated with fu-
sion protein at 7 days of follow-up. We observed a fundusFigure 7 Results of corneal neovascularization (CNV) analysis. A: Table
different depth of the cornea. B: CNV extension at day 7. Percentage of an
the periphery to the center.red reflex and lack of corneal abscess in all PF animals
(Figure 3A). SLPI and Buffer groups showed opaque light
reflex at the fundus red reflex test. In addition, corneal
abscess was found in one SLPI animal and in 3 Buffer
animals. In these groups there were different degrees of
corneal opacity.
Corneal opacity
Fluorescent dye staining of the cornea six hours after
alkali injury showed severe destruction of the 3 mm
central epithelium in the three groups. At day 7, there
was a significant difference in the corneal haze score
between the three groups (P = 0.0137). PF-MC treated
eyes (2.33 ± 0.210) regained the corneal transparencyshowing percentage of rats of each treated group with CNV at
imals of the studied groups that showed neovessels at each field from
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structures through cornea. Not all the corneas treated
with Buffer (3.667 ± 0.210) or SLPI (3.167 ± 0.307) re-
gained transparency (Figure 3B).
Corneal epithelium
Three days postinjury. PF-MC animals had a stratified
epithelium with three layers except in one animal. The
degree of stratification was greater than that seen in the
other animal groups (Additional file 1: Table S1A).
Seven days postinjury. Histological analysis revealed
a stratified corneal epithelium with at least three layers
in all PF-MC (Additional file 1: Table S1C). The mor
phology of cells looked rather normal in this group of
animals. However, the other groups of animals dis-
closed a thin corneal epithelium with one or two layers.
In some cases there was an erratic corneal healing
(Figure 4).Figure 8 Representative VEGF immunofluorescence staining of corne
Buffer. VEGF revels in red the presence of neovessels in the cornea of the
D: Healthy control.Cell count of the corneal stroma
Three days post injury. PF-MC animals had a reduced
number of PMNs and total cells than that observed in
SLPI and Buffer animals (Additional file 2: Table S2A).
Seven days post injury. The number of cells counted in
the corneal stroma was much lower in animals treated
with PF-MC than in the other treated groups (Figure 5).
Similar differences were found whether the center or per-
iphery of the cornea was considered (Additional file 3).
The quantity of PMN cells was significantly reduced in
animals under PF-MC treatment compared to other ani-
mals (Figure 6). The exclusion of cases that had corneal
abscess (severe corneal infection with opacity) did not
modify the degree of differences within groups.
Corneal neovascularization
At 7 days postinjury PF-MC animals had only superficial
neovessels while the other animals also had vessels inal sections at day 7 after alkali-injury treated with PF-MC, SLPI or
treated rats, indicated by white arrows. A: Buffer. B: SLPI. C: PF-MC.
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Only animals that received buffer showed neovessels
growth into the six fields of recording (Figure 7B). Inter-
estingly, blood vessels among PF-MC animals were found
in only one field.
At 3 days postinjury there were some neovessels in the
cornea of SLPI and buffer groups. PF-MC animals showed
very few corneal neovessels.Immunofluorescence
Staining of VEGF was much more extended in the cor-
nea treated with buffer than in the other groups of ani-
mals at day 7 (Figure 8).Discussion
We have analyzed the topical effect of a new fusion pro-
tein made up of SLPI and N-terminal portion of the pro-
tease inhibitor Trappin-2 in a rat model of corneal alkali
injury. Animals treated with the PF-MC had less corneal
inflammation and neovascularization than that found in
rats treated with SLPI or buffer.
The characteristics and potential effects of the protein
fusion have been previously reported. Cementoin (a ter-
minal of Elafin) brings SLPI the capacity to unite to
other molecules present in the intercellular interstitium
by transglutamination. The SLPI is retained in the site
where the transglutaminase enzyme is present [18].
All the animals treated with the PF-MC showed cor-
neal clarity and retinal red reflex at seven days of follow-
up. No corneal abscess was observed. It is known that
SLPI has antimicrobial effect [7,13,22]. The relative
higher effect of SLPI in the PF-MC might have contrib-
uted to prevent the development of a serious corneal ab-
scess as we observed in the other groups of animals.
Corneal neovascularization was found within the three
groups of animals at 7 days postinjury. Nevertheless, the
extension of angiogenesis was much lower in the PF-MC
group and vessels were only seen in the superficial part
of the cornea. It is known that neovessels develop in the
middle to the anterior stroma of the cornea [23]. We ob-
served the presence of vessels in the deeper third of the
cornea in the cases of severe inflammation. The findings
of this study suggest the possibility of a direct relation-
ship between inflammation and depth of hemangiogen-
esis in the corneal stroma.
The histological examination was carried out by two
investigators, double blinded, to avoid bias. The differ-
ence between them was tested but it was not significant.
The mean of both examiners was included in our re-
search study. The number of total cells and PMNs in the
corneal stroma was much more reduced in PF-MC ani-
mals compared to animal groups treated with SLPI or
Buffer. The greater extent of VEGF immunoreactivity incorneas of buffer treated animals compared to the other
groups correlated with the histological findings.
Conclusion
Topical treatment of the fusion protein made up of SLPI +
Cementoin showed good anti-inflammatory and antiangio-
genic properties in a rat model of corneal alkali injury. New
applications of this fusion protein are being tested in other
ocular diseases.
Additional files
Additional file 1: Statistical Analysis of Epithelium Layers Count at
one 40X field in sections of healthy and alkali injured corneas
treated with PF-MC, SLPI or Buffer. A: Count in the Center of the
Corneas at day 3. B: Count in the Periphery of the Corneas at day 3.
C: Count in the Center of the Corneas at day 7. D: Count in the Periphery
of the Corneas at day 7.
Additional file 2: Statistical Analysis of Polymorphonuclear
Neutrophils Count at one 40X field in sections of healthy and alkali
injured corneas treated with PF-MC, SLPI or Buffer. A: Count in the
Center of the Corneas at day 3. B: Count in the Periphery of the Corneas
at day 3. C: Count in the Center of the Corneas at day 7. D: Count in the
Periphery of the Corneas at day 7.
Additional file 3: Statistical Analysis of Total Cell Count at one 40X
field in sections of healthy and alkali injured corneas treated with
PF-MC, SLPI or Buffer. A: Count in the Center of the Corneas at day 3.
B: Count in the Periphery of the Corneas at day 3. C: Count in the Center of
the Corneas at day 7. D: Count in the Periphery of the Corneas at day 7.
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